

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

McLACHLAN *et al.*

Appl. No.: 10/509,131

§ 371 date: September 20, 2005

For: **Novel Gene Targets and Ligands
that Bind Thereto for Treatment
and Diagnosis of Colon Carcinomas**

Confirmation No.: 6721

Art Unit: 1643

Examiner: Harris, Alana M

Atty. Docket: 2159.0640004/EKS/DLL

Reply to Unity of Invention Objection

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

In reply to the Office Action dated March 5, 2008, requesting an election of one invention to prosecute in the above-referenced patent application, Applicants hereby provisionally elect to prosecute the invention of **Group III**, represented by claims 4-6. This election is made without prejudice to or disclaimer of the other claims or inventions disclosed.

Additionally, the Examiner has required that Applicants elect a single nucleic acid, protein, primer or antibody. Applicants hereby provisionally elect the nucleic acid of SEQ ID NO:24. This election is made without prejudice to or disclaimer of the other claims or inventions disclosed.


This election is made without traverse.

It is not believed that extensions of time are required, beyond those that may otherwise be provided for in accompanying documents. However, if additional extensions of time are necessary to prevent abandonment of this application, then such

extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor are hereby authorized to be charged to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.


Danielle L. Letting
Agent for Applicants
Registration No. 56,971

Date: September 5, 2008

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

870929_1.DOC